Aeglea Bio Therapeutics Inc (AGLE) CEO Anthony G. Quinn Acquires 6,256 Shares

Share on StockTwits

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn acquired 6,256 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $6.76 per share, for a total transaction of $42,290.56. Following the acquisition, the chief executive officer now owns 277,152 shares of the company’s stock, valued at approximately $1,873,547.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of AGLE traded down $0.39 during trading hours on Friday, hitting $6.48. The company had a trading volume of 91,546 shares, compared to its average volume of 182,536. The company has a market cap of $194.74 million, a P/E ratio of -3.04 and a beta of 0.89. Aeglea Bio Therapeutics Inc has a 52-week low of $6.31 and a 52-week high of $12.00.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). Analysts expect that Aeglea Bio Therapeutics Inc will post -2.19 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Aeglea Bio Therapeutics by 14.3% during the 1st quarter. BlackRock Inc. now owns 1,490,392 shares of the biotechnology company’s stock valued at $11,998,000 after purchasing an additional 186,330 shares during the period. Aisling Capital Management LP purchased a new position in Aeglea Bio Therapeutics during the 4th quarter valued at about $6,506,000. Vanguard Group Inc increased its holdings in Aeglea Bio Therapeutics by 7.9% during the 3rd quarter. Vanguard Group Inc now owns 753,031 shares of the biotechnology company’s stock valued at $7,207,000 after purchasing an additional 55,193 shares during the period. Vanguard Group Inc. increased its holdings in Aeglea Bio Therapeutics by 7.9% during the 3rd quarter. Vanguard Group Inc. now owns 753,031 shares of the biotechnology company’s stock valued at $7,207,000 after purchasing an additional 55,193 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Aeglea Bio Therapeutics by 57.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 450,591 shares of the biotechnology company’s stock valued at $3,627,000 after purchasing an additional 164,366 shares during the period. Institutional investors own 57.21% of the company’s stock.

Several research analysts have recently commented on the company. JPMorgan Chase & Co. assumed coverage on Aeglea Bio Therapeutics in a report on Thursday, March 21st. They issued an “overweight” rating and a $14.00 price objective on the stock. ValuEngine downgraded Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $14.67.

COPYRIGHT VIOLATION NOTICE: “Aeglea Bio Therapeutics Inc (AGLE) CEO Anthony G. Quinn Acquires 6,256 Shares” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4344749/aeglea-bio-therapeutics-inc-agle-ceo-anthony-g-quinn-acquires-6256-shares.html.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Read More: Is the QQQ ETF safe?

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Datarius Credit  Market Capitalization Hits $111,702.00
Datarius Credit Market Capitalization Hits $111,702.00
SafeCoin  24-Hour Trading Volume Reaches $155.00
SafeCoin 24-Hour Trading Volume Reaches $155.00
Zacks: Brokerages Expect Dermira Inc  Will Announce Quarterly Sales of $34.16 Million
Zacks: Brokerages Expect Dermira Inc Will Announce Quarterly Sales of $34.16 Million
Sesen Bio  Sees Unusually-High Trading Volume
Sesen Bio Sees Unusually-High Trading Volume
S4FE Hits Market Cap of $15.33 Million
S4FE Hits Market Cap of $15.33 Million
$2.46 Billion in Sales Expected for Henry Schein, Inc.  This Quarter
$2.46 Billion in Sales Expected for Henry Schein, Inc. This Quarter


© 2006-2019 Ticker Report